Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the role of Wnt/β-catenin signaling in hair follicle regeneration and highlights recent progress in developing hair loss treatments targeting this pathway, but reports no new clinical results.

This study reviewed different hair loss treatments and suggested that microneedling, PRP therapy, hair transplantation, and certain pharmacological and supplementation approaches show varying effectiveness, with some needing further research for confirmation.

This review discusses recent advancements in microneedle technology for hair loss treatment, highlighting their ability to enhance drug delivery and improve hair follicle survival in transplantation, while also exploring their potential integration with tissue engineering to address regeneration challenges.

Proper nutrition and alternative therapies can help manage hair loss.

This review discusses platelet-rich plasma therapy for hair loss and reports no new clinical results, highlighting its potential benefits, mechanisms of action, and areas needing further research.

This study found that among users of glucagon-like peptide-1 receptor agonists, semaglutide and tirzepatide were associated with higher incidences of hair loss, particularly androgenetic alopecia and telogen effluvium, with rapid weight loss identified as a potential contributor to telogen effluvium.

This review discusses alopecia, its pathophysiology, nanotechnology-based drug delivery systems, and related quality of life issues, without reporting new clinical results.

This study concluded that 12 sessions of fractionated thulium laser treatment improved hair density and thickness in patients with pattern hair loss, with further benefits from adding a growth factor solution post-treatment.

Prescription and alternative therapies for hair loss will be compared for effectiveness.

This study found that combining a thulium laser with intra-perifollicular PDRN injections significantly improved hair thickness but not hair counts compared to mesotherapy and PDRN in patients with pattern hair loss.

In this study, machine learning models showed high accuracy in predicting therapeutic outcomes for female pattern hair loss, highlighting the significant impact of age of onset and condition duration on treatment response.

This abstract discusses advancements in hair transplantation technology, highlighting the role of robotics and follicular unit extraction/grafting in achieving excellent clinical outcomes, with adjuvant treatments like platelet-rich plasma, lasers, and stem cells potentially improving the durability and appearance of results.

Fat-derived stem cell therapies can potentially increase hair growth and thickness in people with hair loss.

Fat-derived stem cell therapies can potentially increase hair growth and thickness in people with hair loss.

This review reports that stem cell-based therapies, natural oils, and low-level laser therapy may offer promising and safe alternative treatments for alopecia, although further standardized trials are needed for confirmation.

This review discusses how pesticide exposure leads to hair loss and explores therapeutic options, including conventional and gene therapies, as well as herbal remedies like ginseng and green tea, which may counteract these effects by addressing the toxicological impact on hair follicles.

This study found that cell-free fat extract (CEFFE) enhanced hair growth in mice with androgenetic alopecia by increasing hair follicle density and promoting proliferation while regulating the DHT/AR pathway.

This article discusses the need for rational strategies in developing hair loss drugs targeting specific events in hair follicle cycling, reporting no clinical findings but emphasizing the importance of understanding molecular controls.

Laser and light therapies can help regrow hair but need more research for best results.

This review explores the use of stem cell-based therapies for hair regeneration, highlighting the potential benefits of stem cell-derived conditioned medium, but stresses the need for more rigorous clinical trials to substantiate its efficacy.

Delaying hair loss treatment reduces its effectiveness.

In this triple-blind randomized clinical trial, researchers found that oral minoxidil 0.25 mg tablets were as effective as 2% topical minoxidil for increasing hair diameter and density in women with female pattern hair loss, with similarly minor side effects.

This study found that cilostazol promoted hair growth in human dermal papilla cells and mouse models, suggesting its potential as a therapeutic target for alopecia treatment.

This study found that while both topical cetirizine and minoxidil improved female pattern hair loss, minoxidil was significantly more effective in increasing hair density.

In clinical studies, inhibiting androgen receptor expression using CosmeRNA ARI SAMiRNA micelles effectively treated androgenetic alopecia by significantly increasing hair growth, as reported in this research.

This review discusses telogen effluvium in women and suggests that combining minoxidil with supplementary therapies may enhance treatment outcomes, but it reports no new clinical results.

This article outlines a diagnostic and therapeutic strategy for female functional androgenization, detailed by guidelines and lifestyle recommendations, but reports no new clinical results.

This study observed that autologous PRP and PDRN injections improved hair thickness and density in women with pattern hair loss, with combined therapy showing greater improvement in thickness than PDRN alone.

This review highlights that poor therapeutic responses in female pattern hair loss involve multiple factors, including pharmacogenetic influences and comorbidities. It suggests a framework to improve outcomes by identifying the primary contributors and using personalized treatment strategies.

This study found that minoxidil and finasteride, commonly used for androgenetic alopecia, were associated with different arrhythmia profiles in adverse event reports: minoxidil predominantly with supraventricular arrhythmias and finasteride primarily with ventricular arrhythmias in men.